D.E. Shaw & Co
MXCT icon

D.E. Shaw & Co’s MaxCyte MXCT Stock Holding History

D.E. Shaw & Co’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$141K Sell
200,505
-463,451
-70% -$433K ﹤0.01% 4248
2025
Q4 		$1.03M Buy
663,956
+366,317
+123% +$585K ﹤0.01% 3518
2025
Q3 		$470K Buy
297,639
+276,087
+1,281% +$480K ﹤0.01% 3893
2025
Q2 		$47K Sell
21,552
-60,212
-74% -$146K ﹤0.01% 4174
2025
Q1 		$223K Sell
81,764
-26,837
-25% -$106K ﹤0.01% 3890
2024
Q4 		$452K Buy
108,601
+84,105
+343% +$318K ﹤0.01% 3675
2024
Q3 		$95.3K Buy
+24,496
New +$103K ﹤0.01% 4255
2023
Q4 		– Sell
-25,162
Closed -$78.5K – 4492
2023
Q3 		$78.5K Sell
25,162
-23,420
-48% -$94.2K ﹤0.01% 3877
2023
Q2 		$223K Sell
48,582
-17,626
-27% -$81K ﹤0.01% 3710
2023
Q1 		$328K Buy
+66,208
New +$326K ﹤0.01% 3722
2022
Q2 		– Sell
-45,109
Closed -$315K – 5610
2022
Q1 		$315K Buy
+45,109
New +$308K ﹤0.01% 4626

Other funds holding MXCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Brooklands Fund Management London, United Kingdom $88.9M AUM

D.E. Shaw & Co's MXCT Position: Q1 2026 in Review

D.E. Shaw & Co reduced its MaxCyte (MXCT) stake by 70% in Q1 2026, selling an estimated $433K and leaving 200,505 shares worth $141K. The position accounts for ﹤0.01% of the portfolio, ranked #4248.

D.E. Shaw & Co first reported a position in MXCT in Q1 2022 and has held it in 11 quarters since. The position peaked at $1.03M in Q4 2025. 130 funds tracked by Wall St. Rank hold MXCT as of Q1 2026.

  • D.E. Shaw & Co held 200,505 shares of MaxCyte worth $141K as of Q1 2026.
  • D.E. Shaw & Co sold 463,451 MaxCyte shares in Q1 2026, an estimated $433K.
  • MaxCyte made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #4248 holding.
  • D.E. Shaw & Co first reported a position in MaxCyte in Q1 2022 and has held it in 11 quarters since.
  • D.E. Shaw & Co's MaxCyte position peaked at $1.03M in Q4 2025.
  • 130 funds tracked by Wall St. Rank held MaxCyte as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.